Reviewer’s report

Title: Stereotactic Body Radiotherapy for Organ-Confined Prostate Cancer

Version: 2 Date: 19 November 2009

Reviewer: Michael Papagikos

Reviewer’s report:

The authors have provided a revised manuscript that provides important toxicity and early efficacy data regarding the use of aggressive hypofractionated radiation therapy for men with localized prostate cancer. It is obvious that considerable effort went into this new draft and the reader will benefit from the changes.

Major Compulsory Revisions: NONE

Minor Essential Revisions: NONE

Discretionary Revisions: The introduction of the "cost effectiveness" of the experimental treatment relative to the author's "standard" treatment is interesting but likely beyond the scope of the manuscript. Many centers provide a 28 fraction course of IMRT to this patient population. No reference is provided to any formal cost-benefit analysis in the literature.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: Yes, and I have assessed the statistics in my report.

Declaration of competing interests:

I declare I have no competing interests.